drugset / Trial / NCT05014139
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1
Terminated
37 enrolled
Astellas Pharma Global Development, Inc.
Seagen, a wholly owned subsidiary of Pfizer · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
Timeline
- Start
- 2021-12-07
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfortumab Vedotin | Other / unclassified | — | Other |